Thyroid eye disease (TED) therapy Tepezza – the highest asset in Amgen's $26 billion takeover of Horizon in 2023 – could be facing Level of competition from A neater-to-dose alternate from Sling Therapeutics. Various unfavorable trials of insulin?like growth aspect?one receptor in